Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: Results of the CAMI-GUIDE study

Luigi M. Biasucci, Fulvio Bellocci, Maurizio Landolina, Roberto Rordorf, Antonello Vado, Endrj Menardi, Giovanna Giubilato, Serafino Orazi, Massimo Sassara, Antonello Castro, Riccardo Massa, Antoine Kheir, Gabriele Zaccone, Catherine Klersy, Francesco Accardi, Filippo Crea

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

AimsPatients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can be offered therapy with implantable cardioverter defibrillators (ICDs). Whether plasma biomarkers can help risk stratify for SCD and ventricular arrhythmias (VT/VF) is unclear. Methods and resultsThe primary objective of the CAMI-GUIDE study is to assess the predictive role of C-reactive protein for SCD or VT/VF in ischaemic patients with the ejection fraction 3 mg/L [heart rate (HR) 0.91 (0.50-1.64) P = 0.76], while C-reactive protein >3 mg/L was strongly associated with mortality due to heart failure [HR: 3.17 (1.54-6.54) P = 0.002]. NT-proBNP above median was significantly associated with the primary endpoint [adjusted HR: 1.46 (1.020-2.129) P = 0.042]. A risk function, including the three biomarkers, NYHA class and resting HR, allowed stratification of patient mortality risk from 5 to 50%. Conclusion C-reactive protein >3 mg/L is not associated with SCD or fast VT/VF, however, is a strong predictor of HF mortality. Biomarkers combined with clinical markers allow an excellent risk stratification of mortality at 2 years.

Original languageEnglish
Pages (from-to)1344-1350
Number of pages7
JournalEuropean Heart Journal
Volume33
Issue number11
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Implantable Defibrillators
C-Reactive Protein
Sudden Cardiac Death
Biomarkers
Heart Rate
Mortality
Cardiac Arrhythmias
Heart Failure
Myocardial Infarction

Keywords

  • Brain natriuretic peptide
  • C-reactive protein
  • Implantable cardioverter defibrillator
  • Myocardial infarction
  • Sudden cardiac death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy : Results of the CAMI-GUIDE study. / Biasucci, Luigi M.; Bellocci, Fulvio; Landolina, Maurizio; Rordorf, Roberto; Vado, Antonello; Menardi, Endrj; Giubilato, Giovanna; Orazi, Serafino; Sassara, Massimo; Castro, Antonello; Massa, Riccardo; Kheir, Antoine; Zaccone, Gabriele; Klersy, Catherine; Accardi, Francesco; Crea, Filippo.

In: European Heart Journal, Vol. 33, No. 11, 06.2012, p. 1344-1350.

Research output: Contribution to journalArticle

Biasucci, LM, Bellocci, F, Landolina, M, Rordorf, R, Vado, A, Menardi, E, Giubilato, G, Orazi, S, Sassara, M, Castro, A, Massa, R, Kheir, A, Zaccone, G, Klersy, C, Accardi, F & Crea, F 2012, 'Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: Results of the CAMI-GUIDE study', European Heart Journal, vol. 33, no. 11, pp. 1344-1350. https://doi.org/10.1093/eurheartj/ehr487
Biasucci, Luigi M. ; Bellocci, Fulvio ; Landolina, Maurizio ; Rordorf, Roberto ; Vado, Antonello ; Menardi, Endrj ; Giubilato, Giovanna ; Orazi, Serafino ; Sassara, Massimo ; Castro, Antonello ; Massa, Riccardo ; Kheir, Antoine ; Zaccone, Gabriele ; Klersy, Catherine ; Accardi, Francesco ; Crea, Filippo. / Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy : Results of the CAMI-GUIDE study. In: European Heart Journal. 2012 ; Vol. 33, No. 11. pp. 1344-1350.
@article{124b79d41f6b4984be3bc4c2f6b82e29,
title = "Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: Results of the CAMI-GUIDE study",
abstract = "AimsPatients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can be offered therapy with implantable cardioverter defibrillators (ICDs). Whether plasma biomarkers can help risk stratify for SCD and ventricular arrhythmias (VT/VF) is unclear. Methods and resultsThe primary objective of the CAMI-GUIDE study is to assess the predictive role of C-reactive protein for SCD or VT/VF in ischaemic patients with the ejection fraction 3 mg/L [heart rate (HR) 0.91 (0.50-1.64) P = 0.76], while C-reactive protein >3 mg/L was strongly associated with mortality due to heart failure [HR: 3.17 (1.54-6.54) P = 0.002]. NT-proBNP above median was significantly associated with the primary endpoint [adjusted HR: 1.46 (1.020-2.129) P = 0.042]. A risk function, including the three biomarkers, NYHA class and resting HR, allowed stratification of patient mortality risk from 5 to 50{\%}. Conclusion C-reactive protein >3 mg/L is not associated with SCD or fast VT/VF, however, is a strong predictor of HF mortality. Biomarkers combined with clinical markers allow an excellent risk stratification of mortality at 2 years.",
keywords = "Brain natriuretic peptide, C-reactive protein, Implantable cardioverter defibrillator, Myocardial infarction, Sudden cardiac death",
author = "Biasucci, {Luigi M.} and Fulvio Bellocci and Maurizio Landolina and Roberto Rordorf and Antonello Vado and Endrj Menardi and Giovanna Giubilato and Serafino Orazi and Massimo Sassara and Antonello Castro and Riccardo Massa and Antoine Kheir and Gabriele Zaccone and Catherine Klersy and Francesco Accardi and Filippo Crea",
year = "2012",
month = "6",
doi = "10.1093/eurheartj/ehr487",
language = "English",
volume = "33",
pages = "1344--1350",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy

T2 - Results of the CAMI-GUIDE study

AU - Biasucci, Luigi M.

AU - Bellocci, Fulvio

AU - Landolina, Maurizio

AU - Rordorf, Roberto

AU - Vado, Antonello

AU - Menardi, Endrj

AU - Giubilato, Giovanna

AU - Orazi, Serafino

AU - Sassara, Massimo

AU - Castro, Antonello

AU - Massa, Riccardo

AU - Kheir, Antoine

AU - Zaccone, Gabriele

AU - Klersy, Catherine

AU - Accardi, Francesco

AU - Crea, Filippo

PY - 2012/6

Y1 - 2012/6

N2 - AimsPatients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can be offered therapy with implantable cardioverter defibrillators (ICDs). Whether plasma biomarkers can help risk stratify for SCD and ventricular arrhythmias (VT/VF) is unclear. Methods and resultsThe primary objective of the CAMI-GUIDE study is to assess the predictive role of C-reactive protein for SCD or VT/VF in ischaemic patients with the ejection fraction 3 mg/L [heart rate (HR) 0.91 (0.50-1.64) P = 0.76], while C-reactive protein >3 mg/L was strongly associated with mortality due to heart failure [HR: 3.17 (1.54-6.54) P = 0.002]. NT-proBNP above median was significantly associated with the primary endpoint [adjusted HR: 1.46 (1.020-2.129) P = 0.042]. A risk function, including the three biomarkers, NYHA class and resting HR, allowed stratification of patient mortality risk from 5 to 50%. Conclusion C-reactive protein >3 mg/L is not associated with SCD or fast VT/VF, however, is a strong predictor of HF mortality. Biomarkers combined with clinical markers allow an excellent risk stratification of mortality at 2 years.

AB - AimsPatients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can be offered therapy with implantable cardioverter defibrillators (ICDs). Whether plasma biomarkers can help risk stratify for SCD and ventricular arrhythmias (VT/VF) is unclear. Methods and resultsThe primary objective of the CAMI-GUIDE study is to assess the predictive role of C-reactive protein for SCD or VT/VF in ischaemic patients with the ejection fraction 3 mg/L [heart rate (HR) 0.91 (0.50-1.64) P = 0.76], while C-reactive protein >3 mg/L was strongly associated with mortality due to heart failure [HR: 3.17 (1.54-6.54) P = 0.002]. NT-proBNP above median was significantly associated with the primary endpoint [adjusted HR: 1.46 (1.020-2.129) P = 0.042]. A risk function, including the three biomarkers, NYHA class and resting HR, allowed stratification of patient mortality risk from 5 to 50%. Conclusion C-reactive protein >3 mg/L is not associated with SCD or fast VT/VF, however, is a strong predictor of HF mortality. Biomarkers combined with clinical markers allow an excellent risk stratification of mortality at 2 years.

KW - Brain natriuretic peptide

KW - C-reactive protein

KW - Implantable cardioverter defibrillator

KW - Myocardial infarction

KW - Sudden cardiac death

UR - http://www.scopus.com/inward/record.url?scp=84861830092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861830092&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehr487

DO - 10.1093/eurheartj/ehr487

M3 - Article

C2 - 22285581

AN - SCOPUS:84861830092

VL - 33

SP - 1344

EP - 1350

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 11

ER -